DMACDiaMedica Therapeutics Inc.同业对比
DiaMedica Therapeutics Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMAC本股 | $369M#8 | — | 9.6x#14 | 738.8x#8 | — | -34.0%#13 | -6879.4%#7 | -85.5%#13 | — | — | -0.4%#5 | — |
| LRMR | $402M#1 | — | 3.2x#11 | — | — | -105.5%#15 | — | -130.1%#14 | -350.3%#4 | — | -5.3%#6 | — |
| BBOT | $389M#3 | — | 1.2x#5 | — | — | -80.5%#14 | — | -41.5%#8 | — | — | -54.7%#10 | — |
| BNTC | $397M#2 | — | 2.2x#8 | — | -100.0%#6 | -20.1%#10 | — | -25.7%#5 | — | — | -17.4%#8 | — |
| RCKT | $387M#4 | — | 1.0x#4 | — | — | 13.8%#6 | — | -60.5%#9 | — | — | 16.3%#4 | — |
| BIOA | $377M#6 | — | 1.0x#1 | 41.9x#5 | — | -13.4%#9 | -1031.5%#5 | -21.5%#3 | — | — | — | — |
| RZLT | $378M#5 | — | 3.2x#12 | — | — | -8.7%#8 | — | -63.7%#10 | -72.2%#3 | — | — | — |
| GALT | $374M#7 | — | — | — | — | 34.5%#3 | — | — | — | — | -19.4%#9 | — |
| ENTA | $367M#9 | — | 3.6x#13 | 5.6x#2 | -3.4%#4 | 29.4%#4 | -130.7%#2 | -81.0%#12 | — | — | 66.6%#3 | — |
| PRLD | $363M#10 | — | 2.7x#10 | 29.9x#4 | 73.4%#2 | 21.8%#5 | -861.3%#4 | -74.4%#11 | — | — | 337.5%#2 | — |
| EBS | $355M#11 | — | 1.0x#3 | 0.5x#1 | -28.8%#5 | 127.6%#1 | 13.5%#1 | 15.4%#1 | 8.1%#1 | 6#1 | -11.0%#7 | — |
| GTBP | $354M#12 | 1.5x#1 | 99.1x#15 | — | — | -115.4%#16 | — | -794.5%#15 | — | — | -61.2%#11 | 0.1%#1 |
| EVMN | $342M#13 | 1.7x#2 | 1.2x#6 | 26.3x#3 | 85.7%#1 | -3.1%#7 | -623.6%#3 | -24.8%#4 | — | — | — | — |
| SION | $328M#16 | — | 1.2x#7 | — | — | -22.0%#11 | — | -28.3%#6 | — | — | -67.3%#12 | — |
| CYPH | $328M#15 | 4.8x#3 | 2.4x#9 | 218.8x#6 | 0.0%#3 | 107.4%#2 | -2737.8%#6 | 3.6%#2 | — | — | 882.6%#1 | — |
| CATX | $329M#14 | — | 1.0x#2 | 229.7x#7 | — | -30.1%#12 | -7919.4%#8 | -31.8%#7 | -41.0%#2 | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议